WASHINGTON, D.C., August 26, 2019 – Baker Botts LLP, an international law firm, today announced that it is representing Celgene Corporation for FTC clearance in its planned merger with Bristol-Myers Squibb Company (“BMS”), including the parties’ proposed divestiture of Celgene’s Otezla OTEZLA® (apremilast) business to facilitate a timely closing of the BMS-Celgene merger. The two companies today announced that Celgene and Amgen Inc. entered into an asset purchase agreement, pursuant to which Celgene agreed to sell to Amgen its OTEZLA® (apremilast) product line and related assets for a cash purchase price of $13.4 billion. The press release about the divestiture can be found here.
The Baker Botts team, which is working closely on the matter with a team at Wachtell Lipton, is led by partner Stephen Weissman and associate Steve Pet. Both are located in the Washington, D.C. office. Mr. Weissman previously served as Deputy Director for the FTC’s Bureau of Competition (2013-2015), where he had oversight over the antitrust agency’s pharmaceutical industry investigations.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 725 lawyers practicing throughout a network of 14 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy and technology sectors. Throughout our 179-year history, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.